Shearman & Sterling represented Morgan Stanley, BofA Merrill Lynch, Credit Suisse, Goldman, Sachs & Co., Barclays, Citigroup, Deutsche Bank Securities, J.P. Morgan and SMBC Nikko as joint book-running managers in connection with Amgen’s registered offering of $3.5 billion of investment grade notes, consisting of $750,000,000 of 2.125% senior notes due 2020, $500,000,000 of 2.700% senior notes due 2022, $1,000,000,000 of 3.125% senior notes due 2025 and $1,250,000,000 of 4.400% senior notes due 2045. Amgen is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

The Team